Education
About Us
Working with TipRanks
Follow Us
Innoviva Inc (INVA)
NASDAQ:INVA
INVA Stock Chart & Stats
$22.18
-$0.05(-0.29%)
At close: 4:00 PM EST
$22.18
-$0.05(-0.29%)
Day’s Range― - ―
52-Week Range$16.52 - $25.15
Previous CloseN/A
Volume64.08K
Average Volume (3M)786.11K
Market Cap
$1.64B
Enterprise Value$1.15B
Total Cash (Recent Filing)$550.94M
Total Debt (Recent Filing)$269.02M
Price to Earnings (P/E)5.0
Beta0.20
Next Earnings
May 13, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.94
Shares Outstanding74,073,650
10 Day Avg. Volume829,099
30 Day Avg. Volume786,106
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)3.17
P/FCF Ratio6.88
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit3.50
Enterprise Value/Ebitda3.07
Forecast
1Y Price Target
$37.00Price Target Upside66.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)1.97
Revenue Forecast (FY)$438.67M
Bulls Say, Bears Say
Bulls Say
Clinical ValidationPivotal Phase 3 results published in The Lancet demonstrating non-inferiority versus standard therapy reinforce clinical credibility and can facilitate physician adoption of zoliflodacin.
Regulatory ApprovalFDA approval of NUZOLVENCE (zoliflodacin) for oral treatment of uncomplicated urogenital gonorrhea provides a proprietary product to commercialize and supports potential revenue growth from a differentiated therapy.
Stable Royalty Cash FlowReliable royalty income from established inhaled therapies supplies capital that can be redeployed into infectious disease programs and shareholder returns, supporting strategic flexibility.
Bears Say
Direct CompetitionApproval and planned launch of gepotidacin by GlaxoSmithKline introduces a well‑resourced rival in the gonorrhea market that could limit market share and slow uptake of zoliflodacin.
Payer And Formulary PressureSimultaneous availability of multiple new antibiotics may prompt stricter payer scrutiny and formulary competition, potentially constraining reimbursement and access for zoliflodacin.
Pricing And Exclusivity PressureOverlap in indications with another approved agent could reduce pricing power and limit the practical duration of commercial exclusivity benefits despite regulatory designations.
Innoviva News
INVA FAQ
What was Innoviva Inc’s price range in the past 12 months?
Innoviva Inc lowest stock price was $16.52 and its highest was $25.14 in the past 12 months.
What is Innoviva Inc’s market cap?
Innoviva Inc’s market cap is $1.64B.
When is Innoviva Inc’s upcoming earnings report date?
Innoviva Inc’s upcoming earnings report date is May 13, 2026 which is in 68 days.
How were Innoviva Inc’s earnings last quarter?
Innoviva Inc released its earnings results on Feb 25, 2026. The company reported $1.94 earnings per share for the quarter, beating the consensus estimate of $0.551 by $1.389.
Is Innoviva Inc overvalued?
According to Wall Street analysts Innoviva Inc’s price is currently Undervalued.
Does Innoviva Inc pay dividends?
Innoviva Inc pays a Quarterly dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Innoviva Inc dividends here
What is Innoviva Inc’s EPS estimate?
Innoviva Inc’s EPS estimate is 0.39.
How many shares outstanding does Innoviva Inc have?
Innoviva Inc has 74,073,650 shares outstanding.
What happened to Innoviva Inc’s price movement after its last earnings report?
Innoviva Inc reported an EPS of $1.94 in its last earnings report, beating expectations of $0.551. Following the earnings report the stock price went down -2.888%.
Which hedge fund is a major shareholder of Innoviva Inc?
Currently, no hedge funds are holding shares in INVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innoviva Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.00 (66.82% Upside)
$37.00 (66.82% Upside)
Blogger Sentiment
Bullish
INVA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 478.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.3%
Last 30 Days ▲ 21.7%
Last 30 Days ▲ 21.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.95%
12-Months-Change
Fundamentals
Return on Equity
29.09%
Trailing 12-Months
Asset Growth
22.44%
Trailing 12-Months
Company Description
Innoviva Inc
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
INVA Stock 12 Month Forecast
Average Price Target
$37.00
▲(66.82% Upside)
Technical Analysis
Ownership Overview
8.51% Insiders
21.06% Mutual Funds
7.99% Other Institutional Investors
31.94% Public Companies and
Individual Investors